Management of acetabular bone loss in revision total hip replacement: a narrative literature review

Awadhesh K Pandey1,2, William A Zuke2, Peter Surace2

  • 1Ongwediva Medipark Hospital, Ongwediva, Namibia.

Annals of Joint
|May 2, 2024
PubMed

Insights

Custom triflange acetabular components offer promising midterm results for revision total hip replacement with massive bone loss. While effective, further long-term studies are needed to confirm their superiority over traditional methods.

Area of Science:

  • Orthopedic Surgery
  • Biomaterials Engineering
  • Medical Device Design

Background:

  • Revision total hip replacement (THR) is increasing due to primary THR growth.
  • Acetabular bone loss is a common challenge in revision THR, complicating reconstruction.
  • Massive acetabular defects and pelvic discontinuity present significant surgical hurdles.

Purpose of the Study:

  • To review emerging trends in reconstructing massive acetabular defects during revision THR.
  • To evaluate the efficacy of custom-made acetabular components compared to conventional methods.
  • To assess midterm outcomes, complications, and cost-effectiveness of novel reconstruction techniques.

Main Methods:

  • A narrative review of PubMed and Cochrane databases was conducted.
  • Focused on recent literature concerning mid- to long-term outcomes of revision THR reconstruction.
  • Compared results from various studies on different acetabular reconstruction methods.

Main Results:

  • Custom triflange acetabular components (CTACs) show promise for massive defects and pelvic discontinuity.
  • CTACs report high patient satisfaction, improved function, and high midterm implant survival.
  • Complication and re-revision rates with CTACs appear comparable to conventional methods.

Conclusions:

  • No definitive consensus exists for reconstructing massive acetabular defects in revision THR.
  • While conventional methods manage moderate loss, massive defects remain challenging.
  • CTACs offer a viable solution for massive bone loss, with comparable costs and complications, though long-term data is pending.
Abstract